Cannabigerol (CBG), commonly termed the “mother cannabinoid,” is the non-acidic decarboxylated form of cannabigerolic acid (CBGA)—the foundational enzymatic precursor from which THCA, CBDA, and CBCA are synthesized during plant maturation. While typical mature cannabis flowers express CBG in trace concentrations (< 1.0%), this formulation utilizes proprietary GACP hemp chemotypes selectively bred to disable downstream synthases, resulting in biomass expressing high natural CBGA yields prior to supercritical CO₂ extraction.

Unlike classical phytocannabinoids, CBG acts as a unique pharmacological agent: it exhibits partial agonist activity at both CB1 and CB2 cannabinoid receptors without eliciting psychoactive effects, while demonstrating potent affinity as an alpha-2 adrenergic receptor agonist and moderate 5-HT1A receptor antagonist. Furthermore, CBG modulates transient receptor potential (TRP) channels, notably TRPA1 and TRPV1. Across European clinical practices—particularly in Germany under DAC/NRF compounding monographs, the UK, and Poland—20% CBG Oil is prescribed for inflammatory bowel diseases (Crohn’s, ulcerative colitis), neuroinflammatory conditions, intraocular ocular hypertension, bladder dysfunction, and diurnal mood dysregulation.

Technical Specifications & Certificate of Analysis (CoA)

Sensory & Formulation Characteristics

• Neutral Organoleptic Profile: Mild, smooth, and virtually free of vegetative bitterness or chlorophyll astringency; optimized for patient compliance during prolonged sublingual absorption.

• Fluid Rheology & Dropper Accuracy: Low kinematic viscosity at 20°C–25°C ensures exact volumetric dosing when dispensed via calibrated pharmaceutical glass pipettes (~5 mg active CBG per standardized single drop).

• Carrier Stability: The lipid base of caprylic (C8) and capric (C10) fatty acids provides exceptional oxidative stability, protecting active CBG molecules from thermal degradation and lipid peroxidation.

• Visual Clarity: Brilliant, crystal-clear formulation with no precipitation, turbidity, or phase separation observed across standard accelerated stability testing protocols.

European Compliance, Quality Assurance & Distribution

• EU-GMP Certified Formulation & Fill: Compounded, homogenized, and bottled within certified ISO Class 7 cleanrooms with laminar flow filling zones adhering to EU-GMP Part I & II standards, ensuring complete sterility and lot uniformity.

• Non-Narcotic Regulatory Framework: With THC concentrations verified below 0.05%, this formulation does not fall under statutory narcotics control regulations (BtMG / CanG in Germany, Misuse of Drugs Act in the UK), facilitating frictionless cross-border commercial transit throughout the Schengen area and wider EU territories.

• Accredited Analytical Testing: Every production lot is paired with a comprehensive Certificate of Analysis (CoA) issued by independent ISO/IEC 17025 accredited laboratories, verifying cannabinoid potency, pesticide clearance, heavy metal limits, and microbiological safety.

• Pharmaceutical Packaging Standards: Packaged in amber Type III hydrolytic glass bottles (DIN 18 finish) equipped with child-resistant, tamper-evident dropper caps and graduated pipettes to preserve formulation integrity and prevent photolytic degradation.